MA52216A - Méthodes de traitement de la colite ulcéreuse - Google Patents

Méthodes de traitement de la colite ulcéreuse

Info

Publication number
MA52216A
MA52216A MA052216A MA52216A MA52216A MA 52216 A MA52216 A MA 52216A MA 052216 A MA052216 A MA 052216A MA 52216 A MA52216 A MA 52216A MA 52216 A MA52216 A MA 52216A
Authority
MA
Morocco
Prior art keywords
ulcerative colitis
treatment methods
treatment
methods
ulcerative
Prior art date
Application number
MA052216A
Other languages
English (en)
Other versions
MA52216B1 (fr
Inventor
James Benedict Canavan
Stuart William Friedrich
Kathryn Ann Krueger
Catherine Milch
Jay Lawrence Tuttle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA52216A publication Critical patent/MA52216A/fr
Publication of MA52216B1 publication Critical patent/MA52216B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA52216A 2018-03-30 2019-03-28 Mirikizumab pour le traitement de la colite ulcéreuse MA52216B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
PCT/US2019/024633 WO2019191464A1 (fr) 2018-03-30 2019-03-28 Méthodes de traitement de la colite ulcéreuse
EP19722256.5A EP3773715B1 (fr) 2018-03-30 2019-03-28 Mirikizumab pour le traitement de la colite ulcéreuse

Publications (2)

Publication Number Publication Date
MA52216A true MA52216A (fr) 2021-02-17
MA52216B1 MA52216B1 (fr) 2024-07-31

Family

ID=66429483

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52216A MA52216B1 (fr) 2018-03-30 2019-03-28 Mirikizumab pour le traitement de la colite ulcéreuse

Country Status (29)

Country Link
US (2) US12152072B2 (fr)
EP (2) EP3773715B1 (fr)
JP (4) JP7119114B2 (fr)
KR (1) KR102552693B1 (fr)
CN (1) CN111936165A (fr)
AU (2) AU2019243283C1 (fr)
BR (1) BR112020018099A2 (fr)
CA (1) CA3095297A1 (fr)
DK (1) DK3773715T3 (fr)
EA (1) EA202091989A1 (fr)
ES (1) ES2983809T3 (fr)
FI (1) FI3773715T3 (fr)
HR (1) HRP20240904T1 (fr)
HU (1) HUE067445T2 (fr)
IL (2) IL277514B2 (fr)
LT (1) LT3773715T (fr)
MA (1) MA52216B1 (fr)
MD (1) MD3773715T2 (fr)
MX (1) MX2020010269A (fr)
MY (1) MY202368A (fr)
PL (1) PL3773715T3 (fr)
PT (1) PT3773715T (fr)
RS (1) RS65661B1 (fr)
SG (1) SG11202009526RA (fr)
SI (1) SI3773715T1 (fr)
TW (2) TWI744617B (fr)
UA (1) UA128578C2 (fr)
WO (1) WO2019191464A1 (fr)
ZA (1) ZA202005388B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
CN115427444A (zh) * 2020-02-14 2022-12-02 詹森生物科技公司 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法
BR112022023489A2 (pt) 2020-05-21 2023-03-14 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
WO2022085739A1 (fr) * 2020-10-20 2022-04-28 協和化学工業株式会社 Dispositif de gestion d'essais cliniques, procédé de gestion d'essais cliniques, programme de gestion d'essais cliniques et système de gestion d'essais cliniques
EP4274849A1 (fr) * 2021-01-06 2023-11-15 AbbVie Inc. Méthodes de traitement de la maladie de crohn et de la colite ulcéreuse
BR112023024064A2 (pt) * 2021-05-20 2024-01-30 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
EP4347018A1 (fr) * 2021-05-28 2024-04-10 Eli Lilly and Company Régulation d'anticorps anti-il-23p19 de gènes impliqués dans la rectocolite hémorragique
EP4623001A1 (fr) * 2022-11-22 2025-10-01 Janssen Biotech, Inc. Méthode de traitement de la rectocolite hémorragique avec un anticorps spécifique anti-il23
CN121079321A (zh) 2023-03-10 2025-12-05 伊莱利利公司 治疗溃疡性结肠炎的方法
WO2024255867A1 (fr) * 2023-06-16 2024-12-19 信达生物制药(苏州)有限公司 Utilisation d'un anticorps de sous-unité anti-interleukine 23p19 recombinant dans le traitement d'une maladie intestinale inflammatoire

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2410406T3 (es) * 2005-06-30 2013-07-01 Janssen Biotech, Inc. Anticuerpos anti-IL-23, composiciones, procedimientos y usos
EP3219328B1 (fr) 2005-12-29 2020-06-17 Janssen Biotech, Inc. Compositions, procédés et utilisations d'anticorps humains anti-il-23
ATE554791T1 (de) 2007-02-23 2012-05-15 Schering Corp Gentechnisch hergestellte anti-il-23p19- antikörper
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2635601B1 (fr) * 2010-11-04 2016-07-20 Boehringer Ingelheim International GmbH Anticorps anti-il-23
TWI636063B (zh) 2013-03-08 2018-09-21 美國禮來大藥廠 結合il-23之抗體
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
US20190269757A1 (en) * 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody

Also Published As

Publication number Publication date
JP2022169562A (ja) 2022-11-09
TWI744617B (zh) 2021-11-01
UA128578C2 (uk) 2024-08-21
IL277514A (en) 2020-11-30
BR112020018099A2 (pt) 2020-12-22
US12152072B2 (en) 2024-11-26
EP4327866A3 (fr) 2024-03-20
TWI837532B (zh) 2024-04-01
PT3773715T (pt) 2024-05-27
IL312807A (en) 2024-07-01
JP7331219B2 (ja) 2023-08-22
MY202368A (en) 2024-04-24
KR102552693B1 (ko) 2023-07-07
AU2019243283C1 (en) 2024-05-02
HRP20240904T1 (hr) 2024-10-11
JP2021517156A (ja) 2021-07-15
JP2025020134A (ja) 2025-02-12
LT3773715T (lt) 2024-06-25
SI3773715T1 (sl) 2024-06-28
AU2019243283A1 (en) 2020-09-24
CN111936165A (zh) 2020-11-13
US20210032325A1 (en) 2021-02-04
ZA202005388B (en) 2025-05-28
AU2023248103A1 (en) 2023-11-09
MD3773715T2 (ro) 2024-10-31
JP7119114B2 (ja) 2022-08-16
DK3773715T3 (da) 2024-05-27
SG11202009526RA (en) 2020-10-29
NZ767902A (en) 2024-05-31
MX2020010269A (es) 2020-11-06
MA52216B1 (fr) 2024-07-31
IL312807B1 (en) 2025-02-01
EP4327866A2 (fr) 2024-02-28
JP2023166388A (ja) 2023-11-21
EA202091989A1 (ru) 2021-01-13
EP3773715A1 (fr) 2021-02-17
IL277514B2 (en) 2024-11-01
ES2983809T3 (es) 2024-10-24
JP7571225B2 (ja) 2024-10-22
EP4327866B1 (fr) 2025-12-10
PL3773715T3 (pl) 2024-08-19
FI3773715T3 (fi) 2024-05-30
TW202206104A (zh) 2022-02-16
HUE067445T2 (hu) 2024-10-28
TW201946657A (zh) 2019-12-16
EP3773715B1 (fr) 2024-05-08
RS65661B1 (sr) 2024-07-31
IL312807B2 (en) 2025-06-01
AU2019243283B2 (en) 2023-07-27
US20250034243A1 (en) 2025-01-30
KR20200128101A (ko) 2020-11-11
CA3095297A1 (fr) 2019-10-03
IL277514B1 (en) 2024-07-01
WO2019191464A1 (fr) 2019-10-03

Similar Documents

Publication Publication Date Title
MA52216A (fr) Méthodes de traitement de la colite ulcéreuse
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
EP3426250A4 (fr) Procédés de traitement
EP3423488A4 (fr) Méthodes de traitement du cancer
EP3288383A4 (fr) Méthodes de traitement du cancer
EP3388004A4 (fr) Instrument de traitement
EP3519833A4 (fr) Méthodes de pronostic et de traitement
EP3340971A4 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
EP3409744A4 (fr) Agent de traitement de surface
EP3606531A4 (fr) Méthodes de traitement du cancer
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
EP3405203A4 (fr) Méthodes de traitement du cancer
EP3389634A4 (fr) Méthodes de traitement du cancer
EP3455188C0 (fr) Procede de traitement de laitier
EP3589659A4 (fr) Composés et méthodes de traitement du cancer
MA53882A (fr) Méthodes de traitement de la sclérose en plaques
EP3431566A4 (fr) Agent de traitement de surface
EP3440112A4 (fr) Méthodes de traitement du cancer
EP3610026A4 (fr) Méthodes de traitement du cancer de la vessie
EP3468548A4 (fr) Méthodes de traitement du cancer du pancréas
EP3375108A4 (fr) Traitement dewlan
BR112018000204A2 (pt) métodos de tratamento de colite
EP3389652A4 (fr) Méthodes de traitement du cancer
EP3634422A4 (fr) Méthodes de traitement de la leucodystrophie
EP3619170A4 (fr) Procédé de traitement de l'eau